Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma

• Hauptverfasser: Andrey Moiseyenko (Verfasst von), Franco Muggia (Verfasst von), Thomas Condamine (Verfasst von), Jennifer Pulini (Verfasst von), John E. Janik (Verfasst von), Daniel C. Cho (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2020-11-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Agonists of the co-stimulatory molecule OX40 (CD134) are in clinical assessment alone and in combination with other immunotherapies. Recent pre-clinical studies have suggested that concurrent administration of OX40 agonists with anti-PD1 therapy is detrimental to the efficacy of such combinations an...